AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.
There is no company-specific news to justify the move; however, investors are probably reacting to the U.S. Food and Drug Administration (FDA) approving Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) two Ziihera-containing combination regimens as first-line treatments for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.
Readers should note that in June, Jazz Pharmaceuticals announced a collaboration with AbCellera Biologics to discover next-generation T-cell-engaging multispecific antibodies.
The partnership includes $56 million in upfront payments and potential milestone payments totaling up to $792 million, which could significantly enhance Jazz’s oncology portfolio as it focuses on gastrointestinal cancers.
Technical Analysis
AbCellera Biologics is currently showing strong bullish momentum, trading well above its key moving averages. The 20-day SMA is 36.2% above the 50-day SMA, indicating a solid upward trend that traders should watch closely.
The RSI is currently at 82.82, indicating that AbCellera Biologics is overbought. This high RSI level suggests that while momentum is strong, there may be a pullback or consolidation in the near term.
MACD is above its signal line, indicating bullish momentum for AbCellera Biologics. This positioning suggests that the current trend is likely to continue, but traders should remain cautious of potential reversals given the overbought RSI.
Currently, there are no clear support or resistance levels identified for AbCellera Biologics. If the stock approaches previous highs, traders should watch for signs of either a breakout or a reversal, which could indicate a shift in momentum.
AbCellera Biologics’ moving averages are all trending upward, with the 50-day SMA above the 200-day SMA, reinforcing the long-term bullish trend. This setup indicates that traders can expect continued strength unless there is a significant shift in price action.
Over the past 12 months, AbCellera Biologics has delivered an impressive 185.12% return, highlighting a strong upward trajectory. This performance reflects the company’s solid fundamentals and market positioning, making it a stock to keep on the radar for long-term investors.
ABCL Stock Price Activity: AbCellera Biologics shares were up 15.83% at $12.29 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo via Shutterstock
Login to comment